TERT and cancer: Subgroup analysis based on cancer classification indicated that the TERT rs10069690 polymorphism was associated with an increased risk of gynecological cancer (OR = 1.11, 95% CI: 1.09–1.14, p‐heterogeneity < .001, I2 = 82.0%), gastrointestinal cancer (OR = 1.21, 95% CI: 1.05–1.41, p‐heterogeneity = .035, I2 = 87.2%) and head and neck cancer (OR = 1.21, 95% CI: 1.14–1.29, p‐heterogeneity < .001, I2 = 0.0%).